List Biotherapeutics, Inc. announced that it expects to receive KRW 21.342007114 billion in funding from Daewon Pharmaceutical Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, and other investors
December 29, 2021
Share
List Biotherapeutics, Inc. announced that it will issue 20,000,000 series A preferred shares at issue price of $3 per share for the gross proceeds $60,000,000 in funding on December 30, 2021. The shares will be convertible in common shares at a price of $3 per share. The transaction will include participation from Hana Untact Digital Innovation Fund for 583,334 shares, Gyeonggi Hana Turn around Fund No.2 for 583,333 shares, Daewon Pharmaceutical Co., Ltd. for 1,000,000 shares, TS 2020-13 M&A Investment Fund for 1,333,334 shares, Tigris Fund No.42 for 1,000,000 shares, Korea Investment & Securities Co., Ltd., Investment Arm for 833,334 shares, Smart SF-WE Untact Fund II for 666,667 shares.
The company will issue shares using third party allocation method. The transaction has been approved by the board of directors of the company. The transaction is expected to close on January 14, 2022.
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
List Biotherapeutics, Inc. announced that it expects to receive KRW 21.342007114 billion in funding from Daewon Pharmaceutical Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, and other investors